TD Asset Management Inc Trims Stock Holdings in Ascendis Pharma A/S $ASND

TD Asset Management Inc trimmed its holdings in Ascendis Pharma A/S (NASDAQ:ASND) by 14.9% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 292,090 shares of the biotechnology company’s stock after selling 51,300 shares during the period. TD Asset Management Inc owned approximately 0.48% of Ascendis Pharma A/S worth $50,415,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also bought and sold shares of ASND. Compagnie Lombard Odier SCmA purchased a new position in Ascendis Pharma A/S in the 2nd quarter valued at approximately $39,000. Brooklyn Investment Group boosted its position in shares of Ascendis Pharma A/S by 332.9% in the first quarter. Brooklyn Investment Group now owns 355 shares of the biotechnology company’s stock valued at $55,000 after acquiring an additional 273 shares during the period. LVW Advisors LLC bought a new position in shares of Ascendis Pharma A/S in the second quarter valued at approximately $202,000. Dearborn Partners LLC bought a new position in shares of Ascendis Pharma A/S in the first quarter valued at approximately $203,000. Finally, New Wave Wealth Advisors LLC bought a new position in shares of Ascendis Pharma A/S in the first quarter valued at approximately $222,000.

Ascendis Pharma A/S Stock Performance

Shares of Ascendis Pharma A/S stock opened at $207.12 on Thursday. Ascendis Pharma A/S has a 52-week low of $118.03 and a 52-week high of $216.45. The stock has a market capitalization of $12.78 billion, a price-to-earnings ratio of -40.14 and a beta of 0.41. The company has a fifty day moving average of $198.44 and a 200-day moving average of $176.71.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its quarterly earnings data on Thursday, August 7th. The biotechnology company reported ($0.93) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.42) by $0.49. The business had revenue of $216.28 million during the quarter, compared to analysts’ expectations of $163.17 million. On average, equities research analysts forecast that Ascendis Pharma A/S will post -4.34 earnings per share for the current fiscal year.

Analyst Ratings Changes

ASND has been the subject of a number of analyst reports. Bank of America raised their price objective on shares of Ascendis Pharma A/S from $227.00 to $230.00 and gave the company a “buy” rating in a research report on Tuesday, September 2nd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Ascendis Pharma A/S in a report on Wednesday, October 8th. Wedbush raised their price target on Ascendis Pharma A/S from $212.00 to $220.00 and gave the company an “outperform” rating in a report on Friday, August 8th. Cowen reaffirmed a “buy” rating on shares of Ascendis Pharma A/S in a report on Friday, August 8th. Finally, Wells Fargo & Company reaffirmed an “overweight” rating and issued a $295.00 price target (up previously from $289.00) on shares of Ascendis Pharma A/S in a report on Friday, August 8th. Fifteen investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $248.29.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.